+0.0019  (+0.37%)
Volume (24h): 859.52K Day Range: 0.5151 - 0.5400
Market Cap: 31.45M 52W Range: 0.2051 - 4.20
Mar-13-20 01:00PM Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline UpdateGlobeNewswire
Mar-03-20 09:01PM Advaxis to Present at the 2020 LD Micro Virtual ConferenceGlobeNewswire
Feb-27-20 02:00PM Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° ConferenceGlobeNewswire
Feb-20-20 01:00PM Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer MeetingGlobeNewswire
Feb-16-20 08:03PM The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA DecisionsBenzinga
Feb-13-20 01:00PM Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers SymposiumGlobeNewswire
Feb-11-20 01:00PM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical ProgramGlobeNewswire
Jan-30-20 02:23PM Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical MeetingsGlobeNewswire
Jan-21-20 01:30PM Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct OfferingGlobeNewswire
Jan-07-20 01:00PM Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate CancerGlobeNewswire
Dec-22-19 10:08PM Is Advaxis, Inc. (ADXS) A Good Stock To Buy?Insider Monkey
Dec-20-19 01:00PM Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business UpdateBusiness Wire
10:04AM Did Changing Sentiment Drive Advaxis's (NASDAQ:ADXS) Share Price Down A Disastrous 99%?Simply Wall St.
Dec-04-19 01:00PM Advaxis to Present at 12th Annual LD Micro Main Event Investor ConferenceBusiness Wire
Dec-03-19 01:00PM Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate CancerBusiness Wire
Oct-24-19 01:00PM Advaxis Announces Business and Pipeline UpdateBusiness Wire
Oct-10-19 12:00PM Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery ResearchBusiness Wire
Oct-07-19 12:00PM Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA TrialBusiness Wire
Sep-19-19 10:36AM Is This A Catalyst To Buy Advaxis, Inc. (NASDAQ:ADXS)?Simply Wall St.
Sep-10-19 11:36AM The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For XerisBenzinga
Sep-09-19 12:00PM Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline UpdateBusiness Wire
Aug-22-19 12:00PM Advaxis, Inc. Issues Letter to ShareholdersBusiness Wire
Aug-12-19 10:30AM BriaCell Appoints Richard J. Berman to Board of DirectorsGlobeNewswire
Jul-24-19 11:08AM The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap IndexBenzinga
Jun-27-19 10:50AM Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV StudyBusiness Wire
Jun-21-19 02:14PM Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMTThomson Reuters StreetEvents
Jun-11-19 01:00PM Advaxis, Inc. to Host Earnings CallACCESSWIRE
Jun-10-19 08:05PM Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline UpdateBusiness Wire
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)